Niche radiopharma CPDC operates as a not-for-profit focused on commercialization and clinical development of radiopharmaceuticals for Canadian patients. This presents a sales opportunity to partner on governmentsupported or grant-funded radiopharma initiatives, leveraging CPDC’s established network with industry, academia, and government.

Public-private network With a track record of creating four Canadian commercial entities and collaborations across industry, academia, and government, CPDC can be approached as a gateway partner to navigate regulatory, funding, and distribution pathways for radiopharmaceutical products in Canada.

Funding readiness CPDC has demonstrated funding capability with reported revenue and secured investment (revenue tier and $8.1M funding). Sales conversations can emphasize co-development, grant-aligned programs, and potential for milestone-based collaborations in radiopharmaceutical development.

Leadership continuity Recent executive leadership appointment in 2020 signals active governance and strategic direction. Engaging CPDC’s leadership on joint development programs could accelerate decision-making, regulatory alignment, and market entry planning.

Canadian focus CPDC’s mission centers on improving Canadian patient access to radiopharmaceuticals, suggesting opportunities to tailor local manufacturing, supply agreements, and commercialization strategies that align with Canadian health system procurement and physician needs.